肿瘤标志物的联合检测在胰腺癌诊断中的应用  

A Study the Value of Combined Measurement of Serum Tumor Markers in Diagnosis of Pancreatic Cancer Patients

作　　者：彭莉[1] 李春岚[1] 朱传金[1] 王更记[1] 

机构地区：[1]山东省肿瘤防治研究院检验科,山东济南250117

出　　处：《肿瘤基础与临床》2006年第1期30-31,共2页journal of basic and clinical oncology

摘　　要：目的探讨肿瘤标志物联合检测在胰腺癌诊断中的应用价值。方法采用电化学发光法对胰腺癌患者的血清CA19_9、CA242和CEA进行检测。结果3种肿瘤标志物中敏感性和特异性以CA19_9最好,分别为82.0%和79.8%,联合检测三种肿瘤标志物可提高其敏感性,敏感性可达89.0%。结论联合检测肿瘤标志物有助于胰腺癌的早期诊断。Objective To study the value of combined measurement of multiple serum tumor markers in diagnosis of pancreatic cancer patients. Methods We detected tumor markers CA19-9, CA242 and CEA in patients with pancreatic cancer by electrechemi-luminescence immunoassay （ECLI） .Remits Among these tumor markers：CA19-9 was the best diagnostic index; its sensitivity and specificity were 83,2% and 75.8% ,respectively. The sensitivity of combined assay was 89.0 %. Conclusions These results suggest that the combined assay of tumor markers is helpful in the early diagnosis of pancreatic cancer.

关 键 词：肿瘤标志物 胰腺癌 联合榆测 

分 类 号：R735.9[医药卫生—肿瘤] R730.43[医药卫生—临床医学]